Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enlituo Plus Anyouping and Chemotherapy in First-Line Advanced HNSCC
NCT07791745Phase 3Recruiting
- Sponsor
- Taizhou Mabtech Pharmaceutical
- Start
- Sep 2026
- Primary completion
- Aug 2032
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in head and neck squamous cell carcinoma (HNSCC) comparing Enlituo® with Placebo (2 arms). Primary endpoints: Overall Survival at 2 years and Objective Response Rate at 2 years. Started Sep 2026; status: recruiting.
02
Drugs
cetuximab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT07791745.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07791745.